Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06752356 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Kedrion S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT06752356: Recruiting Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Kedrion S.p.A..
NCT06752356 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Kedrion S.p.A.. The registered enrollment target is 161 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06752356, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Kedrion S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Primary Outcome
The proportion of responders in the 1.0 g/kg KIg10 arm, at week 24 relative to Randomization Baseline week 0, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline.
Conditions Studied
Interventions
- BIOLOGICAL Immune globulin (human) 10% solution for intravenous administration
Study Locations (1)
Texas
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-12-27 |
| Phase | Phase 3 |
What NCT06752356 shows while recruiting
NCT06752356 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Immune globulin (human) 10% solution for intravenous administration is the first listed.
NCT06752356 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06752356 about?
NCT06752356 is a clinical study titled "A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
What is the current status of trial NCT06752356?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2026-04. Estimated completion is 2027-12-27.
What conditions does trial NCT06752356 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT06752356?
The interventions under investigation include: Immune globulin (human) 10% solution for intravenous administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT06752356?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06752356 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06752356's enrollment target sits among peer trials
161 5th of 11 higher than 7 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT07144826 · 161 participants · Early Phase 1
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia